a-Adrenoceptor antagonists have been used for the treatment of male erectile dysfunction (MED). Ro70-0004a003 (Ro70-0004) is a selective and orally active a 1A -adrenoceptor antagonist. The objective of this study was to: (1) pharmacologically elucidate the a 1 -adrenoceptor subtype mediating norepinephrine-induced contraction of human isolated corpus cavernosal tissue and (2) conduct a clinical proof-of-concept study with Ro70-0004 to test the hypothesis that selective a 1A -adrenoceptor blockade would improve erectile function in patients with MED. In vitro organ bath studies were conducted with strips of human isolated corpus cavernosal tissue obtained from patients undergoing penile prosthesis implantation. Prazosin, cyclazosin, RS-100329 and Ro70-0004a003 antagonized norepinephrine-induced contractile responses with af®nity estimates (pK B or pA 2 ) of 8.4, 7.3, 9.2 and 8.8, respectively, consistent with the singular involvement of a 1A -adrenoceptor subtype. A clinical study (single center, observer-blind, randomized, placebocontrolled, extended period Latin-Square crossover design) was conducted in 24 male patients (mean age 44 y) with MED of no established organic cause to evaluate the ef®cacy of a 5-mg oral dose of Ro70-0004. The primary ef®cacy endpoint was the duration of rigidity b60% at the base of the penis measured between 0.5 and 2.5 h post-dose. Rigidity was assessed by penile plethysmography using the RigiScan Plus 1 1 1 device during visual sexual stimulation. The safety and ef®cacy of Ro70-0004 was also assessed. A 50-mg dose of sildena®l was included as a positive control. For the primary ef®cacy endpoint, the mean duration of erection was 9.69 min following administration of placebo, 8.28 min following Ro70-0004, and 22.64 min following sildena®l. Only the difference between sildena®l and placebo reached statistical signi®cance (P`0.05). A similar pattern was observed when measuring a duration of rigidity b 80% at the base of the penis (secondary endpoint). Ro70-0004 was safe and generally well tolerated (only two out of 20 patients reported at least one adverse event). The highly selective a 1A -adrenoceptor antagonist, Ro70-0004, given at a single dose of 5 mg, did not improve erectile function when compared to placebo.
Introduction
Male erectile dysfunction (MED) is de®ned as the inability to attain and maintain a penile erection for satisfactory sexual intercourse. 1 This condition affects approximately 50% of all men 40 ± 70 y of age and occurs more often in men older than 65. 2 Depending on the etiology, MED can be classi®ed as either organic or psychogenic. 3 Organic erectile dysfunction is the result of an acute or chronic physiological condition (80% of cases are secondary to organic disease, 70% of those to arterial or venous abnormalities). Psychogenic erectile dysfunction may involve two mechanisms: direct inhibition from the brain to the spinal centers; excessive sympathetic out¯ow andaor elevated blood catecholamine levels. Indicators of psychogenic erectile dysfunction include acute onset, often related to a speci®c event, with the most common causes being performance anxiety, relationship con¯ict and sexual inhibition. Male erectile dysfunction represents a major clinical problem which, until recently, was poorly treated due to the ineffective andaor invasive treatments available. Sildena®l (Viagra 1 , P®zer), an orally active and ef®cacious type-5 phosphodiesterase (PDE-5) inhibitor approved by the FDA in 1998, has become the current standard therapy for MED. 4 The ef®cacy of 25, 50 and 100 mg doses of sildena®l in improving erectile function has been demonstrated in more than 3000 patients in 21 American and European randomized, double-blind, placebo-controlled, phase III trials lasting up to 6 months. In these studies, 59% of treated patients reported that they were able to both achieve and maintain erections on most to all occasions compared to 15% of those who received placebo. 5 Penile erection is dependent, to a large extent, on relaxation of corpus cavernosum smooth muscle of the penis, which in turn leads to diminished venous out¯ow and penile engorgement. 6 Adequate relaxation of the corpus cavernosum is mainly dependent on release of nitric oxide (NO), a relaxant factor, and also removal of contractile factors such as norepinephrine (NE). 6 It is known that adrenergic stimulation results in contraction of the cavernosal arteries with reduced cavernosal arterial in¯ow as well as contraction of the trabecular smooth muscle leading to collapse of the lacunar spaces. The resultant loss of corporal veno-occlusive function leads to detumescence. It has been suggested that the etiology of MED may be related to impaired corpus cavernosal relaxation andaor heightened corpus cavernosal contractile tone. 7 Sildena®l potentiates NO-mediated cyclic guanosine monophosphate (cGMP)-induced relaxation of corpus cavernosum. 4, 7 The erectile process can also be facilitated by antagonizing NE-induced, a 1 -adrenoceptor mediated contraction of corpus cavernosum. 8 Clinically, non-selective a-adrenoceptor antagonists such as phentolamine have been used for the treatment of MED. 9 These drugs are minimally ef®cacious because side effects such as hypotension, tachycardia and nausea limit the doses which can be used clinically. It has been established that a 1 , but not a 2 , adrenoceptors mediate contraction of human erectile tissue. 6, 7 Molecular and pharmacological studies have indicated the existence of at least three a 1 -adrenoceptor subtypes (a 1A , a 1B and a 1D ). Although human corpus cavernosal tissue is endowed with a 1A -adrenoceptors, 10 functional evidence for their involvement in contractile responses is lacking. It is conceivable that this avenue of research could lead to the development of more ef®cacious and safer drugs for the treatment of MED.
The aim of this study was two-fold: (1) to pharmacologically characterize the a 1 -adrenoceptor subtype mediating contraction of human corpus cavernosum in vitro; and (2) to evaluate the clinical hypothesis that Ro70-0004 (3-(3-{4-[¯uoro-2-(2,2,2-tri¯uoroethoxy)-phenyl]-piperazin-1-yl}-propyl)-5-methyl-1H-pypimidine-2,4-dione mono hydrochloride monohydrate, Figure 1 ), a selective a 1A -adrenoceptor antagonist, will improve erectile function in patients with MED.
Preliminary accounts of the ®ndings have been presented previously at the AUA 95th annual meeting. 11 
Methods

In vitro studies
In order to characterize the a 1 -adrenoceptor subtype(s) mediating contraction of corpus cavernosum tissue, organ bath experiments (as described by Choppin et al. 12 ) were performed on biopsy specimens of human corporal tissue obtained with informed consent from patients undergoing penile prosthesis implantation for impotence. Cumulative concentration ± response curves to norepinephrine, a non-selective adrenoceptor agonist, were constructed, in presence of an a 2 -adrenoceptor antagonist (idazoxan), uptake blockers (cocaine and corticosterone), an inhibitor of prostanoid synthesis (indomethacin), a b-adrenoceptor antagonist (propranolol) and an anti-oxidant (ascorbic acid). Strips of tissue were incubated for 90 min in the absence or presence of antagonist before a second agonist curve was constructed. The antagonists which were examined were prazosin (non selective), cyclazosin (a 1B -adrenoceptor selective), RS-100329 and Ro70-0004 (a 1A -adrenoceptor selective).
Contractions were recorded as changes in tension from baseline and were expressed as a percentage of the maximum response of the ®rst agonist concentration ± effect curve. Agonist concentration ± response curves were ®tted using a nonlinear iterative ®tting program (Origin, Microcal Software, Inc., Northampton, MA) to estimate agonist potency (pEC 50 ). Antagonist af®nities (pK B or pA 2 values) were determined using one or several concentration(s) of each antagonist, as described by Arunlakshana and Schild. 13 
Clinical study
This clinical study design was an observer-blind, randomized, placebo-controlled, extended period Latin-Square study design that was performed at one research center. Twenty-four male MED patients 
Evaluation of oral Ro70-0004a003
A Choppin et al (41.7% black, 58.3% Caucasian), 18 ± 65 y of age (mean age 44 y), with MED of a continual duration of at least 6 months which had no established organic cause based on clinical evaluation and blood tests were enrolled to evaluate the effect of a single dose of Ro70-0004 on erectile function. The safety and tolerability of the study drug was also assessed. The study consisted of four dosing periods at 7-day intervals. On each dosing day, patients were admitted to the research center where they received a single oral dose of either 5 mg of Ro70-0004, 50 mg of sildena®l, or placebo, and the last treatment was repeated on the last dosing day. Patients remained in the research center until all of the 4 h postdoseadischarge study activities had been completed. Penile rigidity was assessed at the base and the tip of the penis using the RigiScan Plus 1 device from 30 min pre-dose to 2.5 h post-dose. Visual sexual stimulation (eg sexually explicit videotapes) occurred from 30 min post-dose to 2.5 h post-dose. Safety data, including adverse effects, study withdrawal reasons, laboratory data, electrocardiograms, and concomitant medications were recorded for each patient. The study termination visit occurred 1 week following the last dose of study drug.
RigiScan Plus 1 measurements exhibit large interpatient variability, therefore a crossover study design was chosen to allow for a within-patient comparison between Ro70-0004 and placebo.
Sildena®l was included in each treatment sequence as an active control to validate the study results.
The primary variable was the cumulative duration of rigidity greater than or equal to 60% at the base of the penis as measured by RigiScan Plus 1 from 30 min post-dose to 2.5 h post-dose. The secondary variables were the cumulative duration of rigidity greater than 60% at the tip and greater than 80% at the base and tip of the penis. Only penile erections during the 2 h of visual sexual stimulation were included.
Per protocol analyses included complete squares of patients with available RigiScan Plus 1 data from all four treatment periods. The primary and secondary variables were analyzed using an analysis of variance (ANOVA) model with terms for sequence, patient within sequence, treatment, period and carry-over. An intent-to-treat analysis was performed on all available RigiScan Plus 1 data using the same ANOVA model.
Results
In vitro studies
Norepinephrine (NE) produced concentrationdependent contraction of the human isolated corpus cavernosal tissue (pEC 50 5.80 AE 0.13, n 4). Prazosin, cyclazosin, RS-100329 and Ro70-0004 produced parallel dextral shifts of the concentration-effect curve to NE with no change in the maximum response (ie Ð consistent with competitive antagonism). The antagonist af®nity estimates obtained in human corpus cavernosum are shown in Table 1 . Binding af®nities at human cloned a 1 -adrenoceptor subtypes are shown for comparison. These results suggest that the a 1A -adrenoceptor subtype mediates contraction of human corpus cavernosum.
Clinical study
Safety results. Single 5 mg doses of Ro70-0004 were safe and generally well tolerated without clinically signi®cant changes in vital signs or laboratory test results. Two out of 20 patients reported at least one adverse effect after receiving a single 5 mg oral dose of Ro70-0004 (Table 2 ). Ro70-0004 was as well tolerated as sildena®l in this study. There were minimal differences of adverse effects for patients dosed with either Ro70-0004 or sildena®l.
Ef®cacy results. Rigidity at the base of the penis:
Following visual sexual stimulation, the mean duration of rigidity b60% at the base of the penis was 9.69 min following administration of placebo, 8.28 min following 5 mg of Ro70-0004, and Rigidity at the tip of the penis: The mean duration of rigidity b60% at the tip of the penis was 5.33 min following administration of placebo, 5.52 min following 5 mg of Ro70-0004, and 9.21 min following 50 mg of sildena®l. The mean duration of rigidity b 80% at the tip of the penis was 1.23 min following administration of placebo, 1.20 min following Ro70-0004, and 3.18 min following sildena®l. Ro70-0004 and sildena®l did not produce a signi®cant effect (P b 0.05 vs placebo).
The ef®cacy data with placebo, Ro70-0004 and sildena®l is summarized in Table 3 .
Discussion
For most patients with erectile dysfunction, oral agents are a preferred treatment over using vacuum pumps, 16 penile prosthesis 17 or injection of vasodilator agents directly into the corpora cavernosa (agents commonly used include papaverine, phentolamine and PGE 1 which have been used singly or in combination. 18 The recent introduction of oral sildena®l, a drug which facilitates the NOac-GMP relaxant mechanism in erectile tissue, has offered MED patients with a new therapeutic option. An alternative therapeutic strategy is to antagonize the a 1 -adrenoceptor contractile pathway. Indeed, cavernosal a-adrenoceptor blockade is known to produce erection 8 and is used for diagnostic and therapeutic purposes, whilst a-adrenoceptor agonists such as metaraminol may be used to reverse this effect. Furthermore, non selective a-adrenoceptor subtype antagonists such as phentolamine, 19 selective a 1 -adrenoceptor antagonists (eg prazosin and moxisylyte) 20 have been evaluated in clinical trials as possible treatments for MED although the systemic adverse effects of these drugs limits their therapeutic value. Given the known heterogeneity of a 1 -adrenoceptor subtypes, efforts to elucidate the functional a 1 -adrenoceptor subtype in human erectile tissue and develop selective drugs for this target may be therapeutically rewarding. Ro70-0004 is a selective a 1A -adrenoceptor antagonist. The selectivity of Ro70-0004 has been demonstrated in contractile assays in native tissues (including human lower urinary tract tissues) and at recombinant a 1 -adrenoceptor subtypes using both binding (Table 1) and functional assays. 14 In the present study, we have characterized the a 1 -adrenoceptor subtype mediating contraction of human corpus cavernosum using a range of selective pharmacological probes. The af®nity estimates of prazosin (non-selective), cyclazosin (a 1B -selective), Ro70-0004 and RS-100329 (a 1A -selective) suggest that the a 1 -adrenoceptor mediating contraction of human erectile tissue equates with the a 1A -adrenoceptor subtype.
Clinically, Ro70-0004 has been evaluated in patients for the treatment of benign prostatic hyperplasia (BPH; this data has not been published). In humans, Ro70-0004 is rapidly absorbed after oral administration (t max 1 ± 2 h) with an elimination half-life of 5 ± 7 h. An oral dose of 5 mg Ro70-0004 yielded plasma drug levels suf®cient to produce selective and long-lasting a 1A -adrenoceptor blockade.
The present study was undertaken to determine whether Ro70-0004 could improve erectile function in MED patients. This study demonstrated unequivocally that a 5 mg dose of Ro70-0004 was ineffective in improving erectile activity as measured by RigiScan Plus 1 in patients with erectile dysfunction with no established organic cause. The clinical study design was validated using sildena®l which did increase penile rigidity at the base of the penis. However, the 5.26 min duration of rigidity b 80% at the base of the penis obtained in this study was lower than what has been reported previously. 21 It should be noted that both Ro70-0004 and sildena®l were safe and well tolerated in this study.
It is well known that the sympathetic nervous system is involved in erectile function. Possible explanations for the failure of an a 1A -adrenoceptor antagonist to produce ef®cacy in this study include (1) a redundancy of contractile mechanisms, (2) the involvement of a 1A -adrenoceptors in cavernosal smooth muscle but not in penile vascular smooth muscle contraction. It is possible, however, that selective antagonism of the a 1A -adrenoceptor 
